In this context, the aim of the present document is to summarize, in the form of a narrative literature review, the currently available data on the main mechanisms of action of GIP/GLP-1 co-agonists and the clinical effects of tirzepatide evaluated in various clinical trials
GLP2 versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial
How does PlexusDx support the decision between these options
Planning for the ongoing investment in health and receiving support throughout the treatment journey is key
Can athletes take glutathione
Start your intake The legitimate access pathway Retatrutide is not currently an FDA-approved medication in the U.S